Recruiting studies: Cdkn2A Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squ
Phase 3 · 5 location(s) · Washington University School of Medicine · NCT04966481 A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid
Phase 1 · 12 location(s) · Bristol-Myers Squibb · NCT07077434 First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tu
Phase 1 · 37 location(s) · Relay Therapeutics, Inc. · NCT05216432 An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Inte
NA · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT05420064 A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus
Phase 2/Phase 3 · 318 location(s) · Bristol-Myers Squibb · NCT07063745 A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
Phase N/A · 1 location(s) · Nuvance Health · NCT03250078 The Cancer of the Pancreas Screening-5 CAPS5)Study
Phase 3 · 9 location(s) · Johns Hopkins University · NCT02000089

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.